Related Experiment Video
Updated: Aug 1, 2026

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
Differences in vasculature between pilocytic and anaplastic astrocytomas of childhood
Benjamin Gesundheit1, Giannoula Klement, Christof Senger
1Department of Paediatrics, New Agent and Innovative Therapy Program, Toronto, Ontario, Canada.
Insights
Anaplastic astrocytoma (AA) has immature vasculature, unlike pilocytic astrocytoma (PA). This suggests AA may respond better to anti-angiogenic therapies targeting its unique vascular profile.
Area of Science:
- Neuro-oncology
- Vascular biology
- Cancer research
Background:
- Childhood pilocytic astrocytoma (PA) and anaplastic astrocytoma (AA) exhibit distinct clinical behaviors and prognoses.
- Aggressive anaplastic astrocytoma (AA) is paradoxically found with lower microvessel density than pilocytic astrocytoma (PA).
Purpose of the Study:
- To investigate the microvasculature differences between pilocytic astrocytoma (PA) and anaplastic astrocytoma (AA).
- To differentiate mature versus immature vessels in PA and AA using specific markers.
Main Methods:
- Utilized antibodies for Factor VIII (FVIII) to identify endothelial cells (ECs) and alpha-smooth muscle actin (alpha-SMA) to assess vessel maturity.
- Examined the expression patterns of vascular endothelial growth factor (VEGF) and its receptor, flt-1/VEGFR-1.
Main Results:
- Pilocytic astrocytoma (PA) predominantly features large, mature, alpha-SMA-positive vessels (54.5% maturation index).
- Anaplastic astrocytoma (AA) is characterized by small, immature, alpha-SMA-negative vessels (6.1% maturation index).
- VEGF was mainly in PA astrocytes, while flt-1/VEGFR-1 was detected in AA tumor cells.
Conclusions:
- The immature vasculature of anaplastic astrocytoma (AA) suggests increased susceptibility to anti-angiogenic therapies.
- VEGF and flt-1/VEGFR-1 expression in AA tumor cells may indicate an autocrine growth function, supporting anti-angiogenesis as a therapeutic strategy for AA.
Background:
The clinical manifestations of childhood pilocytic astrocytoma (PA) and anaplastic astrocytoma (AA) markedly differ, especially in the time to progression and prognosis. Because of the aggressive course and poor survival rate of AA, one would expect it to be associated with a high angiogenic index. Counterintuitively, we often find higher microvessel density counts in PA than in AA.
Procedure:
We examined the differences in type or density of microvasculature between the two neoplasms. To differentiate established, mature vessels from immature growing ones, we used antibodies to Factor VIII (FVIII) to stain endothelial cells (ECs) of blood vessels and alpha-smooth muscle actin (alpha-SMA) antibodies to stain vessels supported by adventitia.
Results:
We found that large, mature, alpha-SMA-positive vessels predominated in PA, and small, immature, alpha-SMA-negative vessels in AA. The vessel maturation index was 54.5% for PA, and 6.1% for AA. Immunostaining with vascular endothelial growth factor (VEGF) and anti-flt-1/VEGF receptor-1 antibodies showed distinct tissue patterns. VEGF immunoreactivity occurred mainly in the processes of the tumor astrocytes in PA; the opposite was observed in AA. flt-1/VEGFR-1 was detected in the tumor cells of AA but not in those of PA.
Conclusions:
We propose that the predominance of small, alpha-SMA-negative vessels in AA represents immature, unstable vasculature with a potentially greater susceptibility to anti-angiogenic therapy. The expression of both flt-1 and VEGF by AA tumor cells also suggests a possible autocrine growth-promoting function for VEGF in addition to its role as paracrine pro-angiogenic growth factor for activated ECs, thus making anti-angiogenesis an attractive therapeutic target in the treatment of AA.
More Related Videos
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014
08:46A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)
Published on: March 7, 2017